On the recommendation of the data safety and monitoring board, @REMAP_CAP is declaring efficacy of #tocilizumab with an OR of 1.87 for benefit on a combination of survival and length of time patients received organ support in ICU, compared with standard care [...]
This finding has a high degree of statistical certainty, with 99.75% probability of benefit for tocilizumab compared to no immune modulation […]
This conclusion is based on the first 303 critically ill patients randomized in the #COVID19 immune modulation domain; due to rapid recruitment since that interim analysis, the final analysis will have hundreds more patients included [...]
The data is being analyzed for full release and publication, waiting on patients randomized as of today to reach their primary outcome [...]
Relative benefits of tocilizumab, compared with other agents in the immune-modulation domain (sarilumab, interferon-beta-1a, or anakinra) cannot be stated at this point and more data will emerge over the coming months as randomization continues [...]
Also, lopinavir/ritonavir is no longer available for randomization, after a declaration of futility (OR of 0.67, with a 99.9% probability of futility) [...]
Many thanks to our sponsors partners and sites @anzicrc @anzicsctg @ClinResearchNZ @UMCUtrecht @capticcanada @SMHcriticalcare @CCCTG_ @CIHR_IRSC @GCAResearch @APPRISE_CRE @minderoo @PREPARE_EUROPE
Full protocol available here: remapcap.org/protocol-docum…
A very special thanks to @ICNARC And @NIHRresearch for leading efforts in the United Kingdom, where a majority of patients in this domain have been randomised.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
